RET and medullary thyroid gland carcinoma: The small proportion of RET-negative cases in our series is similar to that in the phase 3 ZETA trial, where only 2/231 (1%) of patients in the vandetanib group and 6/100 (6%) of patients in the placebo group with MTC were RET negative [2].